Effects of interferon beta-1a and -1b over time: 6-Year results of an observational head-to-head study

Acta Neurologica Scandinavica

Volumn 113, Issue 4, 2006, Pages 241-247

  Patti, F ^a   Pappalardo, A ^a   Florio, C ^a   Politi, G ^b   Fiorilla, T ^a   Reggio, E ^a   Reggio, A ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

interferon; Efficacy in clinical practice; Relapsing remitting multiple sclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; ARTICLE; DEPRESSION; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION SITE REACTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYALGIA; OUTPATIENT; RELAPSE; SCORING SYSTEM; SIDE EFFECT; SPASTICITY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644905869     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00565.x     Document Type: Article

References (29)

1. T he IFNB M ultiple S clerosis S tudy G roup Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 1993 43 655 61
2. J acobs LD C ookfair DL R udick RA et al. the Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis Ann Neurol 1996 39 285 94
3. PRISMS (P revention of R elapses and D isability by I nterferon β-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis Lancet 1998 352 1498 504
4. P aty DW L i DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UCB MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 1993 43 662 7
5. S imon JH J acobs LD C ampion M et al. the Multiple Sclerosis Comparative Research Group (MSCRG) Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis Ann Neurol 1998 43 79 87
6. S imon JH L ull J J acobs LD et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β-1a Neurology 2000 55 185 92
7. F isher E R udick RA S imon JH et al. Eight-year follow-up study of brain atrophy in patients with MS Neurology 2004 59 1412 20
8. C alabresi PA Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology 2002 58 Suppl. 4 S10 22
9. P oser CM P aty DW S cheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 1983 13 227 31
10. K urtzke JF Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 1983 33 1444 52
11. L ublin FD R eingold SC Defining the clinical course of multiple sclerosis: results of an international survey Neurology 1996 46 907 11
12. O rmerod IEC M iller DH M c D onald WI et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurologic lesions: a quantitative study Brain 1987 110 1579 616
13. B ertolotto A Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis Curr Opin Neurol 2004 17 241 6
14. B ertolotto A G illi F S ala A et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients Neurology 2003 60 634 9
15. P aolillo A P ozzilli C G iugni E et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta Eur J Neurol 2002 9 645 55
16. R io J T intorè M N os C T ellez N G alan I M ontalban X Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre J Neurol 2005 252 795 800
17. W ingerchuk DM N oseworthy JH Randomized controlled trials to assess therapies for multiple sclerosis Neurology 2002 58 S40 8
18. B enson K H artz AJ A comparison of observational studies and randomized, controlled trials N Engl J Med 2000 342 1878 86
19. C onfavreux C V ukusic S M oreau T A deleine P Relapses and progression of disability in multiple sclerosis N Engl J Med 2000 343 1430 8
20. T rojano M L iguori M P aolicelli D et al. for the Southern Italy MS Group Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy Mult Scler 2003 9 451 7
21. H aas J F irzlaff M S chmidt M Comparison of new immunomodulatory treatment in the early stages of MS Mult Scler 2001 7 Suppl. 1 S15
22. S eijo-Martinez M A migo MC A rias M et al. for the MS Study Group of Galicia, Spain Experience of interferon beta (IFN-β) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain) Mult Scler 2001 7 Suppl. 1 S54
23. D ubois BD K eenan E P orter BE et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre J Neurol Neurosurg Psychiatry 2003 74 946 9
24. M ilanese C L a Mantia L P alumbo R et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-out and treated patients J Neurol Neurosurg Psychiatry 2003 74 1689 92
25. O ztekin N O ztekin MF An open label trial comparing the effects of IFN-β-1a (Rebif), (Avonex), and IFN-β-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapy Mult Scler 2001 7 Suppl. 1 S96
26. L immroth V M alessa R K alski G W ernsdörfer C A comparison of the efficacy and tolerability of interferon beta (IFN-β) products used as initial or follow-up therapy for the treatment of relapsing multiple sclerosis: results from the QUASIMS study Neurology 2004 62 Suppl. 5 A155 6
27. K han OA T selis AC K amholz JA G arbern JY L ewis RA L isak RP A prospective, open-label treatment trial to compare the effect of IFN-β-1a (Avonex), IFN-β-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis Eur J Neurol 2001 8 141 8
28. D urelli L V erdun E B arbero P et al. the Independent Comparison of Interferon Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN) Lancet 2002 359 1453 60
29. Panitch H G oodin DS F rancis G et al. Randomized comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) trial Neurology 2002 59 1496 506